Stock Taper
SCREENER COMPARE ANY 2 STOCKS
AKBA
AKEBIA THERAPEUTICS, INC.
NASDAQ
$0.91
▼ DOWN 1.39% (-0.01)

KEY STATISTICS

Market Cap$243.20 M
52w High$3.22
52w Low$0.81
Dividend Yield—
Frequency—
P/E-9.25
Volume6.45M
Shares Out.268.26M

COMPANY

LEADERSHIP

John Butler
CHIEF EXECUTIVE
John Butler

COMPENSATION 2026

Salary$864,010
Stock Awards$2,164,338
Incentive Plan Pay$580,973
All Other Comp.$18,220
Total$5,652,339

ABOUT

SECTOR
Healthcare
WENT PUBLIC
March 20, 2014
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
194

PRICE TARGET

Target High$1.00
Target Low$1.00
Target Median$1.00
Target Consensus$1.00

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.$46.55M
NOV
9
MON

PRICE

$0.91 ▼ DOWN 1.39% (−$0.01)
$0.91$0.93$0.949:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM0.91

About Akebia Therapeutics, Inc.

https://www.akebia.com ↗

Akebia Therapeutics develops and commercializes kidney disease treatments, including vadadustat in Phase III trials and Auryxia, with global collaborations to address anemia and iron deficiency in CKD patients.

INDUSTRY

Biotechnology

A PRODUCT AKEBIA THERAPEUTICS, INC. IS KNOWN FOR

Vafseo (vadadustat) Tablets
Vafseo (vadadustat) Tablets

Vafseo, FDA-approved in March 2024, is a once-daily oral medication for anemia caused by CKD in adults on dialysis, offering a new standard of care for approximately 500,000 U.S. patients.

COMPETITORS

COMPETITOR
AMGN COMPARE
AZN COMPARE
GSK COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Product$56.79M — $51.99M ▼—
Auryxia— — $36.19M —
License Collaboration And Other Revenue$1.98M $3.33M ▲— $2.36M ▼
Supply Agreement— — — $500K
License Collaboration And Other Revenue Royalties— — — $100K

ETFS HOLDING THIS STOCK

ETFS HOLDING
69
LISTED HERE
14
RANKED BY POSITION SIZE
VTS.AX
0.00% · 7.9M
XSU.TO
0.01% · 6.7M
FESM
0.03% · 1.9M
SCHA
0.01% · 1.3M
PRFZ
0.01% · 449.6K
GSSC
0.04% · 437.0K
ZPRR.DE
0.01% · 429.0K
SBIO
0.12% · 315.9K
XRS2.DE
0.01% · 239.8K
RSSL
0.01% · 122.7K
URTY
0.00% · 10.5K
PQ
PQSG
0.26% · 9.2K
VETS
0.02% · 5.0K
RESM
0.01% · 510

INSTITUTIONAL OWNERSHIP

SHARES OWNED
36.29%
HOLDERS
252
TOP 12 OF 252 · RANKED BY POSITION SIZE
Blackrock, Inc.
19.3M sh · $31.1M
Vanguard Group Inc
16.0M sh · $25.79M
State Street Corp
13.7M sh · $22.04M
Blackrock Inc.
11.6M sh · $11.87M
Geode Capital Management, LLC
6.5M sh · $8.97M
Alerce Investment Management, L.P.
5.7M sh · $10.92M
Goldman Sachs Group Inc
4.7M sh · $7.58M
Citadel Advisors LLC
4.7M sh · $7.51M
Morgan Stanley
4.3M sh · $11.78M
Renaissance Technologies LLC
4.0M sh · $10.79M
Ubs Group AG
3.6M sh · $9.95M
Qube Research & Technologies Ltd
3.2M sh · $8.75M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
DIRECTOR, OFFICER: CEO AND PRESIDENT
Butler John P.
Sale · 350.0K shares
2026-08-06
★
DIRECTOR, OFFICER: CEO AND PRESIDENT
Butler John P.
Purchase · 350.0K shares
2026-08-06
★
OFFICER: SVP, CFO, CBO & TREASURER
Ostrowski Erik
Sale · 56.0K shares
2026-06-29
★
DIRECTOR
FRIESON RON
Purchase · 35.7K shares
2026-06-17

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 2
MARKET PERFORM 1
OVERWEIGHT 1
4 GRADES IN THE LAST 12 MONTHS
Leerink Partners MARKET PERFORM HC Wainwright & Co. BUY BTIG BUY Piper Sandler OVERWEIGHT

SECTORS PEERS

PEERPRICE
CRVS$14.46COMPARE
OLMA$10.69COMPARE
RIGL$45.89COMPARE
FDMT$15.83COMPARE
ZVRA$11.87COMPARE
PRTA$9.45COMPARE
CMPX$2.40COMPARE
GOSS$0.15COMPARE